The novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · see citing works

Diffusible, nonfibrillar ligands derived from Aβ _1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works

HMG-1 as a Late Mediator of Endotoxin Lethality in Mice

Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L. V., et al. (1999) · Science · doi:10.1126/science.285.5425.248 · Cited by 3,386 · see citing works

Intracellular amyloid-β in Alzheimer's disease

LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942 · see citing works

P <scp>ROTOFIBRILS</scp> , P <scp>ORES</scp> , F <scp>IBRILS, AND</scp> N <scp>EURODEGENERATION</scp> : Separating the Responsible Protein Aggregates from The Innocent Bystanders

Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · see citing works

Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability

Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452 · see citing works

Alzheimer's disease: strategies for disease modification

Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,060 · see citing works

Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine

De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · see citing works

Amyloid oligomers: formation and toxicity of Aβ oligomers

Sakono, M., & Zako, T. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07568.x · Cited by 602 · see citing works

Amyloid beta oligomers induce impairment of neuronal insulin receptors

Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · see citing works

Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins

Martínez, P., & Blasco, M. A. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3025 · Cited by 530 · see citing works

Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats

Studer, L., Tabar, V. S., & McKay, R. D. G. (1998) · Nature Neuroscience · doi:10.1038/1105 · Cited by 529 · see citing works

Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress

Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., et al. (1995) · Experimental Neurology · doi:10.1006/exnr.1995.1080 · Cited by 352 · see citing works

Telomeres: Cancer to Human Aging

Stewart, S. A., & Weinberg, R. A. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104518 · Cited by 336 · see citing works

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 322 · see citing works

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study

Bernhardt, S. L., Gjertsen, M. K., Trachsel, S., Møller, M., Eriksen, J. A., Meo, M. L., Buanes, T. A., & Gaudernack, G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603437 · Cited by 303 · see citing works

A novel serum-free medium for the expansion of human mesenchymal stem cells

Chase, L. G., Lakshmipathy, U., Solchaga, L. A., Rao, M. S., & Vemuri, M. C. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt8 · Cited by 257 · see citing works

Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling

Magdesian, M. H., Carvalho, M., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, L., Garcia-Abreu, J., & Ferreira, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707108200 · Cited by 251 · see citing works

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

Brunsvig, P. F., Aamdal, S., Klemp, M., Kvalheim, G., Markowski-Grimsrud, C. J., Sve, I., Dyrhaug, M., Trachsel, S., Møller, M., Eriksen, J. A., et al. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0145-7 · Cited by 246 · see citing works

The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays

Smith, L., Watson, M. B., O’Kane, S. L., Drew, P. J., Lind, M., & Cawkwell, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0190 · Cited by 235 · see citing works

High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage

Lange, S. S., Mitchell, D. L., & Vásquez, K. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803181105 · Cited by 231 · see citing works

Reply to “Survival of expanded dopaminergic precursors is critical for clinical trials”

Studer, L., Tabar, V. S., & McKay, R. D. G. (1998) · Nature Neuroscience · doi:10.1038/2774 · Cited by 220 · see citing works

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

Greten, T. F., Forner, A., Korangy, F., Nkontchou, G., Barget, N., Ayuso, C., Ormandy, L. A., Manns, M. P., Beaugrand, M., & Bruix, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-209 · Cited by 210 · see citing works

Age-dependent Accumulation of Soluble Amyloid β (Aβ) Oligomers Reverses the Neuroprotective Effect of Soluble Amyloid Precursor Protein-α (sAPPα) by Modulating Phosphatidylinositol 3-Kinase (PI3K)/Akt-GSK-3β Pathway in Alzheimer Mouse Model

Jiménez, S., Torres, M., Vizuete, M., Sanchez-Varo, R. M., Sánchez‐Mejías, E., Trujillo‐Estrada, L., Carmona‐Cuenca, I., Caballero, C., Ruano, D., Gutiérrez, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209718 · Cited by 190 · see citing works

Routine identification of proteins from sodium dodecyl sulfate‐polyacrylamide gel electrophoresis (SDS‐PAGE) gels or polyvinyl difluoride membranes using matrix assisted laser desorption/ionization‐time of flight‐mass spectrometry (MALDI‐TOF‐MS)

Fernandez, J., Gharahdaghi, F., & Mische, S. M. (1998) · Electrophoresis · doi:10.1002/elps.1150190619 · Cited by 180 · see citing works

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Broersen, K., Rousseau, F., & Schymkowitz, J. (2010) · Alzheimer's Research &amp; Therapy · doi:10.1186/alzrt36 · Cited by 168 · see citing works

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

Brunsvig, P. F., Kyte, J. A., Kersten, C., Sundstrøm, S. H., Møller, M., Nyakas, M., Hansen, G. L., Gaudernack, G., & Aamdal, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1385 · Cited by 159 · see citing works

Production of neurons, astrocytes and oligodendrocytes from mammalian CNS stem cells

Chojnacki, A. K., & Weiss, S. (2008) · Nature Protocols · doi:10.1038/nprot.2008.55 · Cited by 155 · see citing works

Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients

Kyte, J. A., Gaudernack, G., Dueland, S., Trachsel, S., Julsrud, L., & Aamdal, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0184 · Cited by 111 · see citing works

Does the p75 neurotrophin receptor mediate Aβ‐induced toxicity in Alzheimer's disease?

Coulson, E. J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03905.x · Cited by 99 · see citing works

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001

Inderberg, E. M., Trachsel, S., Lislerud, K., Rasmussen, A., & Gaudernack, G. (2012) · OncoImmunology · doi:10.4161/onci.20426 · Cited by 98 · see citing works

Telomere-independent functions of telomerase in nuclei, cytoplasm, and mitochondria

Chiodi, I., & Mondello, C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00133 · Cited by 96 · see citing works

Cancer vaccination with telomerase peptide GV1001

Kyte, J. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902897631 · Cited by 95 · see citing works

A Ganglioside-induced Toxic Soluble Aβ Assembly

Yamamoto, N., Matsubara, E., Maeda, S., Minagawa, H., Takashima, A., Maruyama, W., Michikawa, M., & Yanagisawa, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606202200 · Cited by 91 · see citing works

Diphosphorylation and involvement of extracellular signal-regulated kinases (ERK1/2) in glutamate-induced apoptotic-like death in cultured rat cortical neurons

Jiang, Q., Gu, Z., Zhang, G., & Jing, G. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02364-1 · Cited by 88 · see citing works

Telomerase (hTERT 611–626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells

Kokhaei, P., Palma, M., Hansson, L., Österborg, A., Mellstedt, H., & Choudhury, A. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2006.10.006 · Cited by 60 · see citing works

Erythropoietin Increases the Motility of Human Bone Marrow-Multipotent Stromal Cells (hBM-MSCs) and Enhances the Production of Neurotrophic Factors From hBM-MSCs

Koh, S., Noh, M., Cho, G. W., Kim, K. S., & Kim, S. H. (2008) · Stem Cells and Development · doi:10.1089/scd.2008.0040 · Cited by 53 · see citing works

Vaccination of patients with cutaneous melanoma with telomerase-specific peptides

Hunger, R. E., Lang, K. K., Markowski-Grimsrud, C. J., Trachsel, S., Møller, M., Eriksen, J. A., Rasmussen, A., Braathen, L. R., & Gaudernack, G. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1061-z · Cited by 47 · see citing works

Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer

Shaw, V. E., Naisbitt, D. J., Costello, E., Greenhalf, W., Park, B., Neoptolemos, J. P., & Middleton, G. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.92 · Cited by 40 · see citing works

Culture of Mouse Neural Stem Cell Precursors

Currle, D. S., Hu, J. S., Kolski‐Andreaco, A., & Monuki, E. S. (2007) · Journal of Visualized Experiments · doi:10.3791/152 · Cited by 38 · see citing works

Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3‐kinase pathway

Lee, Y. J., Park, K. H., Park, H., Kim, Y. J., Lee, K., Kim, S. H., & Koh, S. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06297.x · Cited by 37 · see citing works

New treatment options for advanced pancreatic cancer

Middleton, G., Ghaneh, P., Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.5.673 · Cited by 31 · see citing works

Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma

Schlapbach, C., Yerly, D., Daubner, B., Yawalkar, N., & Hunger, R. E. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.02.001 · Cited by 27 · see citing works

Inhibitors beta-amyloid-induced toxicity by modulating the Akt signaling pathway

Nakagami, Y. (2004) · Drug News & Perspectives · doi:10.1358/dnp.2004.17.10.873917 · Cited by 25 · see citing works

l-DOPA-induced neurotoxicity is reduced by the activation of the PI3K signaling pathway

Park, H., Lee, K., Kim, S. H., Lee, Y. J., & Koh, S. (2009) · Toxicology · doi:10.1016/j.tox.2009.09.011 · Cited by 21 · see citing works

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis

Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Domı́nguez, L., Shea, J., Dokholyan, N. V., Simone, A. D., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 676 · see citing works

Ageing and the telomere connection: An intimate relationship with inflammation

Zhang, J., Rane, G., Dai, X., Shanmugam, M. K., Arfuso, F., Samy, R. P., Lai, M. K. P., Kappei, D., Kumar, A. P., & Sethi, G. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.11.006 · Cited by 386 · see citing works

Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease

Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 204 · see citing works

Telomerase-Targeted Cancer Immunotherapy

Mizukoshi, E., & Kaneko, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081823 · Cited by 123 · see citing works

Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies

Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94 · see citing works

Quantitative assessment of telomerase components in cancer cell lines

Akıncılar, S. C., Low, K. C., Liu, C. Y., Yan, T. D., Oji, A., Ikawa, M., Li, S., & Tergaonkar, V. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.02.035 · Cited by 79 · see citing works

Targeting aging and age-related diseases with vaccines

Wu, R., Sun, F., Zhang, W., Ren, J., & Liu, G.-H. (2024) · Nature Aging · doi:10.1038/s43587-024-00597-0 · Cited by 66 · see citing works

Telomerase: Key regulator of inflammation and cancer

Wu, L., Fidan, K., Um, J., & Ahn, K. S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104726 · Cited by 61 · see citing works

The non-canonical functions of telomerase: to turn off or not to turn off

Romaniuk-Drapała, A., Paszel-Jaworska, A., Totoń, E., Lisiak, N., Hołysz, H., Królak, A., Grodecka-Gazdecka, S., & Rubiś, B. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4496-x · Cited by 61 · see citing works

Akt signaling pathway: a potential therapy for Alzheimer’s disease through glycogen synthase kinase 3 beta inhibition

Limantoro, J., de Liyis, B. G., & Sutedja, J. C. (2023) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00751-2 · Cited by 59 · see citing works

Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals

Park, H.-H., Yu, H.-J., Kim, S., Kim, G., Choi, N.-Y., Lee, E.-H., Lee, Y. J., Yoon, M.-Y., Lee, K.-Y., & Koh, S.-H. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.05.022 · Cited by 49 · see citing works

In vitro models for neurotoxicology research

Barbosa, D. J., Capela, J. P., Bastos, M. D. L., & Carvalho, F. D. (2015) · Toxicology Research · doi:10.1039/c4tx00043a · Cited by 49 · see citing works

Status and future directions of clinical trials in Alzheimer's disease

Plascencia‐Villa, G., & Perry, G. L. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.022 · Cited by 48 · see citing works

Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: A phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

Koh, S.-H., Kwon, H. S., Choi, S. H., Jeong, J. H., Na, H. R., Lee, C. N., Yang, Y., Lee, A. Y., Lee, J.-H., Park, K. W., et al. (2021) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-021-00803-w · Cited by 39 · see citing works

Peptide Immunotherapy in Vaccine Development

Yang, H. M., & Kim, D. S. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.03.001 · Cited by 37 · see citing works

Telomerase increasing compound protects hippocampal neurons from amyloid beta toxicity by enhancing the expression of neurotrophins and plasticity related genes

Baruch-Eliyahu, N., Rud, V., Braiman, A., & Priel, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-54741-7 · Cited by 37 · see citing works

Targeting epigenetics: A novel promise for Alzheimer’s disease treatment

Jeremic, D., Jiménez‐Díaz, L., & Navarro‐López, J. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102003 · Cited by 36 · see citing works

Potential roles of telomeres and telomerase in neurodegenerative diseases

Wang, J., Liu, Y., Xia, Q., Xia, Q., Wang, B., Yang, C., Liang, J., & Liu, X. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.046 · Cited by 34 · see citing works

Exploring the Causal Relationship Between Telomere Biology and Alzheimer’s Disease

Kuan, X.-Y., Fauzi, N. S. A., Ng, K. Y., & Bakhtiar, A. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03337-4 · Cited by 35 · see citing works

Lessons from antiamyloid-β immunotherapies in Alzheimer's disease

Plascencia‐Villa, G., & Perry, G. L. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00019-9 · Cited by 34 · see citing works

Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials

Harris, G. A., Hirschfeld, L. R., González, M. I., Pritchard, M. C., & May, P. C. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01775-x · Cited by 31 · see citing works

Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures

Shen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025) · Cells · doi:10.3390/cells14191506 · Cited by 32 · see citing works

The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease

Yu, H.-J., & Koh, S. (2017) · Hanyang Medical Reviews · doi:10.7599/hmr.2017.37.1.18 · Cited by 29 · see citing works

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27 · see citing works

Telomerase Biology Associations Offer Keys to Cancer and Aging Therapeutics

Smith‐Sonneborn, J. (2019) · Current Aging Science · doi:10.2174/1874609812666190620124324 · Cited by 23 · see citing works

The role of telomerase and viruses interaction in cancer development, and telomerase-dependent therapeutic approaches

Jeda, A. S., Badrzadeh, F., Esghaei, M., & Abdoli, A. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100323 · Cited by 24 · see citing works

Interplay between PI3k/AKT signaling and caspase pathway in Alzheimer disease: mechanism and therapeutic implications

Bhatia, V., Sharma, V. V., Chandel, A., & Rattan, A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01715-z · Cited by 21 · see citing works

GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition

Kim, Y., Lee, D. Y., Jo, H., Go, C., Yang, J., Kang, D., & Kang, J. S. (2021) · Aging · doi:10.18632/aging.202242 · Cited by 21 · see citing works

A randomised, placebo‐controlled, multicentre, Phase 2 clinical trial to evaluate the efficacy and safety of GV 1001 in patients with benign prostatic hyperplasia

Moon, K. T., Yoo, T. K., Kwon, S. Y., Ha, J. Y., Byun, S., Kim, J. H., Chung, J. I., Kim, T., Moon, H. S., Kim, S., et al. (2018) · British Journal of Urology · doi:10.1111/bju.14233 · Cited by 20 · see citing works

Neuroprotective Effects of GV1001 in Animal Stroke Model and Neural Cells Subject to Oxygen-Glucose Deprivation/Reperfusion Injury

Kwon, H. S., Kim, Y. E., Park, H., Son, J., Choi, H., Lee, Y. J., Kim, H. Y., Lee, K., & Koh, S. (2021) · Journal of Stroke · doi:10.5853/jos.2021.00626 · Cited by 18 · see citing works

A novel telomerase-derived peptide GV1001-mediated inhibition of angiogenesis: Regulation of VEGF/VEGFR-2 signaling pathways

Kim, J. H., Cho, Y., Ahn, E., Kim, S., Han, S., Kim, S. J., Bae, G., Oh, J. S., & Seo, D. W. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101546 · Cited by 17 · see citing works

Differential Effects of Isoxazole-9 on Neural Stem/Progenitor Cells, Oligodendrocyte Precursor Cells, and Endothelial Progenitor Cells

Koh, S., Liang, A. C., Takahashi, Y. K., Maki, T., Shindo, A., Osumi, N., Zhao, J., Lin, H., Holder, J. C., Chuang, T. T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138724 · Cited by 16 · see citing works

Interaction between Amyloid Beta Toxicity and the PI3K Pathway in Alzheimer’s Disease

Choi, H., & Koh, S. H. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000269 · Cited by 17 · see citing works

GV1001 modulates neuroinflammation and improves memory and behavior through the activation of gonadotropin-releasing hormone receptors in a triple transgenic Alzheimer's disease mouse model.

Park, H., Kwon, H., Lee, K.-Y., Kim, Y. E., Son, J., Choi, N.-Y., Lee, E. J., Han, M.-H., Park, D. W., Kim, S., et al. (2023) · Brain, behavior, and immunity · doi:10.1016/j.bbi.2023.10.021 · Cited by 13 · see citing works

Protective effect of telomerase-based 16-mer peptide vaccine (GV1001) on inferior epigastric island skin flap survivability in ischaemia-reperfusion injury rat model

Lee, Y. K., Nata’atmadja, B. S., Kim, B. H., Pak, C. S., & Heo, C. Y. (2016) · Journal of Plastic Surgery and Hand Surgery · doi:10.1080/2000656x.2016.1235046 · Cited by 15 · see citing works

A telomerase-derived peptide regulates reactive oxygen species and hepatitis C virus RNA replication in HCV-infected cells via heat shock protein 90

Lee, S.-A., Kim, J., Sim, J., Kim, S. G., Kook, Y., Park, C., Kim, H., & Kim, B. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.160 · Cited by 15 · see citing works

Tracking and protection of transplanted stem cells using a ferrocenecarboxylic acid-conjugated peptide that mimics hTERT

Park, H.-H., Lee, K., Park, D. W., Choi, N.-Y., Lee, Y. J., Son, J., Kim, S., Moon, C., Kim, H., Rhyu, I. J., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.009 · Cited by 15 · see citing works

Inhibition of the NLRP3 Inflammasome Activation/Assembly through the Activation of the PI3K Pathway by Naloxone Protects Neural Stem Cells from Ischemic Condition

Kim, J. Y., Hwang, M., Choi, N.-Y., & Koh, S.-H. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03418-4 · Cited by 14 · see citing works

Updates on pharmacological treatment for Alzheimer’s disease

Tipton, P. W. (2023) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.96286 · Cited by 16 · see citing works

Novel Peptide Vaccine GV1001 Rescues Hearing in Kanamycin/Furosemide-Treated Mice

Kim, S. H., Jung, G., Kim, S., & Koo, J. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00003 · Cited by 14 · see citing works

Outcomes of Peptide Vaccine GV1001 Treatment in a Murine Model of Acute Noise-Induced Hearing Loss

Lee, S., Han, J. J., Lee, S.-Y., Jung, G., Min, H. J., Song, J., & Koo, J. (2020) · Antioxidants · doi:10.3390/antiox9020112 · Cited by 14 · see citing works

hTERT peptide fragment GV1001 demonstrates radioprotective and antifibrotic effects through suppression of TGF‑β signaling

Chen, W., Shin, K., Kim, S., Shon, W., Kim, R., Park, N., & Kang, M. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3566 · Cited by 11 · see citing works

GV1001 Induces Apoptosis by Reducing Angiogenesis in Renal Cell Carcinoma Cells Both In Vitro and In Vivo

Kim, G. E., Jung, A. R., Kim, M. Y., Lee, J. B., Im, J. H., Lee, K. W., Park, Y. H., & Lee, J. Y. (2018) · Urology · doi:10.1016/j.urology.2017.10.038 · Cited by 11 · see citing works

The Novel Peptide Vaccine GV1001 Protects Hearing in a Kanamycin-induced Ototoxicity Mouse Model

Kim, S. Y., Jung, G., Shim, Y. J., & Koo, J. (2018) · Otology & Neurotology · doi:10.1097/mao.0000000000001911 · Cited by 11 · see citing works

Role of Senescence and Neuroprotective Effects of Telomerase in Neurodegenerative Diseases

Ding, X., Liu, X., Wang, F., Wang, F., & Geng, X. (2019) · Rejuvenation Research · doi:10.1089/rej.2018.2115 · Cited by 11 · see citing works

Effects of aspirin and clopidogrel on neural stem cells

Hwang, M., Park, H.-H., Choi, H., Lee, K., Lee, Y. J., & Koh, S. (2017) · Cell Biology and Toxicology · doi:10.1007/s10565-017-9412-y · Cited by 9 · see citing works

GV1001, hTERT Peptide Fragment, Prevents Doxorubicin-Induced Endothelial-to-Mesenchymal Transition in Human Endothelial Cells and Atherosclerosis in Mice

Chen, W., Kim, S., Kim, S. Y., Beheshtian, C., Kim, N., Shin, K.-H., Kim, R. H., Kim, S., & Park, N.-H. (2025) · Cells · doi:10.3390/cells14020098 · Cited by 8 · see citing works

Alzheimer’s Disease Pharmacology

Plascencia‐Villa, G., & Perry, G. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00018-9 · Cited by 6 · see citing works

Potential roles of telomeres and telomerase in neurodegenerative diseases

Shao, J., Wang, J., Li, B., & Liu, C. (2024) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2023.41 · Cited by 6 · see citing works

Advances in Alzheimer’s disease: mechanistic insights and therapeutic targets

Jia, Y.-J., Ge, Y., Li, B., Yang, Y., Chen, H., Liu, J., Guo, J., Yu, J., Ye, K., Wang, J., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-2991-7 · Cited by 5 · see citing works

Computational vaccinology approach: Designing an efficient multi-epitope peptide vaccine against Cryptococcus neoformans var. grubii’s heat shock 70KDa proteinPreprint

Elhassan, R. M., Alsony, N. M., Othman, K. M., Izz-Aldin, D. T., Alhaj, T. A., Ali, A. A., Abashir, L. A., Ahmed, O. H., & Hassan, M. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/534008 · Cited by 5 · see citing works

Senolytic Vaccines from the Central and Peripheral Tolerance Perspective

Vasilieva, M., Shatalova, R. O., Matveeva, K. S., Shindyapin, V. V., Minskaia, E., Ivanov, R. A., & Shevyrev, D. (2024) · Vaccines · doi:10.3390/vaccines12121389 · Cited by 5 · see citing works

Fluorescent Phenotyping of Blood Cells Using a Differential Sensing Strategy: Differentiating Physiological Aging Stages and Neuro‐Degenerative Disease Drugs

Lee, J. H., Yoon, H. Y., Lee, H., Kang, D. M., Bak, Y., Biazruchka, I., Lim, S., Kim, S., Kim, Y. K., Kim, D., et al. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202302916 · Cited by 4 · see citing works

Glia-Like Cells from Human Mesenchymal Stem Cells Protect Neural Stem Cells in anIn VitroModel of Alzheimer's Disease by Reducing NLRP-3 Inflammasome

Hwang, M., Song, S. H., Chang, M., & Koh, S. (2021) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2021.20.1.1 · Cited by 3 · see citing works

A randomized, active-controlled, multicenter, phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia

Shin, T. J., Ha, J. Y., Kwon, S. Y., Park, D. J., Kim, J. H., Lee, S. W., Jeong, I. G., Lee, J. Y., Yoo, T. K., Kim, T., et al. (2024) · Prostate International · doi:10.1016/j.prnil.2024.10.001 · Cited by 3 · see citing works

Immunotherapeutics for AD: A Work in Progress

Sharma, A., Anand, J. S., & Kumar, Y. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210903101522 · Cited by 3 · see citing works

Exploring the Enigma of 5-ARIs Resistance in Benign Prostatic Hyperplasia: Paving the Path for Personalized Medicine

Lin, Z., Liu, Z., & Niu, Y. (2023) · Current Urology Reports · doi:10.1007/s11934-023-01188-z · Cited by 2 · see citing works

GV1001, an hTERT-Derived Peptide, Prevents Cisplatin-Induced Nephrotoxicity by Preserving Mitochondrial Function

Chen, W., Beheshtian, C., Kim, S., Kim, S., Kim, S., & Park, N.-H. (2025) · Cells · doi:10.3390/cells14221818 · Cited by 2 · see citing works

GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects

Park, H., Kwon, H. S., Lee, K., Kim, Y. E., Son, J., Choi, N.-Y., Han, M., Park, D. W., Kim, S., & Koh, S. (2024) · Aging · doi:10.18632/aging.205489 · Cited by 2 · see citing works

A telomerase-derived peptide vaccine inhibits laser-induced choroidal neovascularization in a rat model

Lee, E. K., Kim, Y. J., Shon, W., & Yu, H. G. (2019) · Translational research · doi:10.1016/j.trsl.2019.10.001 · Cited by 2 · see citing works

GV1001 reduces pathological 4R tau and functional deficits in models relevant to progressive supranuclear palsy

Jang, K.-B., Kang, D., Lee, M.-H., Lukianenko, N., Kim, Y. K., Lim, S., Kim, S., & Cho, H. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-42195-7 · Cited by 1 · see citing works

GV1001: repurposing a telomerase-derived peptide for neurological therapeutics

Suk, K., & Lee, W.-H. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2674652 · Cited by 1 · see citing works

New Perspectives for Treatment in Alzheimer’s Disease

Loureiro, J. C., Silva, L. F. D. A. L. E., Pais, M. V., & Forlenza, O. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_10 · Cited by 1 · see citing works

Investigating the Protective Effects of Telomerase Reverse Transcriptase on Neuronal Metabolism and Resistance to Amyloid-beta

Singh, O. (2017) · Scholarship@Western (Western University)

Age-related disease: Effective intervention

Fossel, M., & Cooke, J. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15500-0.00013-x

REVOLUTIONIZING ALZHEIMER’S THERAPEUTICS: FROM MICROTECHNOLOGIES TO AI-DRIVEN INNOVATIONS

Lahiri, A., V., B., K., M., & R., A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i3.53726

Nonamyloid-beta active immunization for the treatment of Alzheimer’s disease

Triplett, O., Varda, N., Decourt, B., & Sabbagh, M. N. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2551352

Additional file 2 of Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

Koh, S.-H., Kwon, H. S., Choi, S. H., Jeong, J. H., Na, H. R., Lee, C. N., Yang, Y., Lee, A. Y., Lee, J.-H., Park, K. W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14329456

Additional file 1 of Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

Koh, S.-H., Kwon, H. S., Choi, S. H., Jeong, J. H., Na, H. R., Lee, C. N., Yang, Y., Lee, A. Y., Lee, J.-H., Park, K. W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14329453

A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease

Lee, Y., Nam, H., Lee, J. D., Ko, Y. J., Kim, E. J., Ha, S., Kim, N., Koo, J. W., Son, T., Kim, S., et al. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01729-9

Biomaterial platforms for enhanced stem cell therapy in ischemic stroke

Sun, Z., Zhao, J., Li, J., Ma, X., Wang, Z., Wang, Y., Li, Y., Bai, Y., Wei, D., & Jiang, W. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124427

Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates

Manzine, P. R., Carrasco, M., Fernandes, T. A. A., Alves, S. S., Guzman, L., Driouech, L., Millet, M., Cairasco, N. G., Olloquequi, J., Juan, M. E., et al. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2710112

GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects

Park, H., Kwon, H. S., Lee, K., Kim, Y. E., Son, J., Choi, N.-Y., Han, M., Park, D. W., Kim, S., & Koh, S. (2024) · Aging · doi:10.18632/aging.205489 · Cited by 2 · see citing works

Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals

Park, H.-H., Yu, H.-J., Kim, S., Kim, G., Choi, N.-Y., Lee, E.-H., Lee, Y. J., Yoon, M.-Y., Lee, K.-Y., & Koh, S.-H. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.05.022 · Cited by 49 · see citing works

The Catalytic Subunit of Telomerase Protects Neurons Against Amyloid β‐Peptide‐Induced Apoptosis

Zhu, H., Fu, W., & Mattson, M. P. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750117.x · Cited by 175 · see citing works

S100B protects LAN‐5 neuroblastoma cells against Aβ amyloid‐induced neurotoxicity via RAGE engagement at low doses but increases Aβ amyloid neurotoxicity at high doses

Businaro, R., Leone, S., Fabrizi, C., Sorci, G., Donato, R., Lauro, G. M., & Fumagalli, L. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20785 · Cited by 96 · see citing works

Telomerase increasing compound protects hippocampal neurons from amyloid beta toxicity by enhancing the expression of neurotrophins and plasticity related genes

Baruch-Eliyahu, N., Rud, V., Braiman, A., & Priel, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-54741-7 · Cited by 37 · see citing works